Live Breaking News & Updates on Trigen Laboratories

Stay updated with breaking news from Trigen laboratories. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Alora Pharmaceuticals, LLC announces the availability of Once-Daily Relexxii® for the treatment of Attention Deficit Hyperactivity Disorder (ADHD)

/PRNewswire/ Alora Pharmaceuticals, LLC, the parent company of Vertical Pharmaceuticals, LLC, announced today the commercial availability of Relexxii®. ....

Sovereign Pharmaceuticals , Prnewswire Alora Pharmaceuticals , Acella Holdings , Alora Pharmaceuticals , Drug Delivery Technology , Avion Pharmaceuticals , Alora Family Of Companies , Acella Pharmaceuticals , Osmotica Pharmaceuticals , Vertical Pharmaceuticals , Attention Deficit Hyperactivity Disorder , Alora Pharmaceutical , Full Prescribing Information , Alora Family , Trigen Laboratories , Mcfarland Parkway , Alora Pharmaceuticals ,

AcelRx Pharmaceuticals Announces Closing of Divestment of DSUVIA® to Alora Pharmaceuticals

/PRNewswire/ AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of. ....

Vince Angotti , Osmotica Pharmaceuticals , European Medicines Agency , Department Of Defense , Sovereign Pharmaceuticals , Acella Pharmaceuticals , Alora Pharmaceuticals , Acelrx Pharmaceuticals Inc , Avion Pharmaceuticals , Acelrx Pharmaceuticals , Oxford Finance , Chief Executive Officer , Breakthrough Device Designation Status , Trigen Laboratories ,

AcelRx Pharmaceuticals Reports Full Year and Fourth Quarter 2022 Financial Results and Provides Corporate Update

Divestment of DSUVIA® to Alora Pharmaceuticals expected to close the week of April 3, 2023 AcelRx advancing its proprietary Niyad™ nafamastat program with FDA. ....

United States , Andrea Angelini , Jeffrey Deweese , Ashley Sikand , Vince Angotti , University Of Padova , Osmotica Pharmaceuticals , European Medicines Agency , Office Rhinology Procedures , Avion Pharmaceuticals , Acelrx Pharmaceuticals Inc , Department Of Defense , Sovereign Pharmaceuticals , Prnewswire Acelrx Pharmaceuticals Inc , Alora Pharmaceuticals , Uniformed Services University Of The Health Sciences , Exchange Commission , Acella Pharmaceuticals , Drug Administration , Niyad Emergency Use Authorization , New Drug Application , Chief Executive Officer , Emergency Use Authorization , Recent Corporate , European Launch , Otolaryngology Case ,

AcelRx Pharmaceuticals Announces Divestment of DSUVIA® to Alora Pharmaceuticals

Agreement with Alora Pharmaceuticals provides AcelRx with 15% royalties on commercial sales, 75% royalties on Department of Defense (DoD) sales, up to $116.5. ....

Vince Angotti , Department Of Defense Do , Department Of Defense , Avion Pharmaceuticals , Alora Pharmaceuticals , Acella Pharmaceuticals , Exchange Commission , Acelrx Pharmaceuticals Inc , Osmotica Pharmaceuticals , European Medicines Agency , Sovereign Pharmaceuticals , Niyad Emergency Use Authorization , Acelrx Pharmaceuticals , Chief Executive Officer , Emergency Use Authorization , Art Deas , Trigen Laboratories , Breakthrough Device Designation Status , Private Securities Litigation Reform Act , Health Care Amp Hospitals , Medical Pharmaceuticals , Pharmaceuticals , New Products Amp Services ,

Alora Pharmaceuticals Celebrates Acquisition of Monarch Manufacturing Facility

/PRNewswire/ Alora Pharmaceuticals, LLC, is pleased to announce that its wholly owned subsidiary, Sovereign Pharmaceuticals, LLC, has acquired, through. ....

United States , Avion Pharmaceuticals , Alora Pharmaceuticals , Acella Pharmaceuticals , Osmotica Pharmaceutical , Prnewswire Alora Pharmaceuticals , Trigen Laboratories , Sovereign Pharmaceuticals , Fort Worth , Art Deas , Vertical Pharmaceuticals , Alora Pharmaceuticals ,